Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893–2917 (2010).
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J. Clin. Gastroenterol. 35(5 Suppl. 2), S72–S78 (2002).
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908–943 (2012).
   PubMed Web of Science ®Google Scholar
• Gandini S, Botteri E, Iodice S et al. Tobacco smoking and cancer: a meta-analysis. Int. J. Cancer 122(1), 155–164 (2008).
   PubMed Web of Science ®Google Scholar
• Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S79–S86 (2004).
   PubMed Web of Science ®Google Scholar
• Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J. Hepatol. 47(4), 506–513 (2007).
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ. Health Perspect. 118(6), 818–824 (2010).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3), 1020–1022 (2011).
   PubMed Web of Science ®Google Scholar
• Trevisani F, D’intino PE, Morselli-Labate AM et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 34(4), 570–575 (2001).
   PubMed Web of Science ®Google Scholar
• Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: from diagnosis to treatment. World J. Hepatol. 7(8), 1020–1029 (2015).
   PubMedGoogle Scholar
• Liu X, Cheng Y, Sheng W et al. Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J. Surg. Oncol. 102(3), 249–255 (2010).
   PubMed Web of Science ®Google Scholar
• Sterling RK, Wright EC, Morgan TR et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am. J. Gastroenterol. 107(1), 64–74 (2012).
   PubMed Web of Science ®Google Scholar
• Chen DS, Sung JL, Sheu JC et al. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 86(6), 1404–1409 (1984).
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol. Clin. Oncol. 1(4), 593–598 (2013).
   PubMedGoogle Scholar
• Colli A, Fraquelli M, Casazza G et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol. 101(3), 513–523 (2006).
   PubMed Web of Science ®Google Scholar
• Achkar JP, Araya V, Baron RL, Marsh JW, Dvorchik I, Rakela J. Undetected hepatocellular carcinoma: clinical features and outcome after liver transplantation. Liver Transpl. Surg. 4(6), 477–482 (1998).
   PubMedGoogle Scholar
• Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S133–S143 (2004).
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Manini MA, Iavarone M et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59(5), 638–644 (2010).
   PubMed Web of Science ®Google Scholar
• Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247(2), 311–330 (2008).
   PubMed Web of Science ®Google Scholar
• Libbrecht L, Bielen D, Verslype C et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl. 8(9), 749–761 (2002).
   PubMed Web of Science ®Google Scholar
• Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J. Hepatol. 7(12), 1632–1651 (2015).
   PubMed Web of Science ®Google Scholar
• Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 61(3), 1056–1065 (2015).
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126(4), 1005–1014 (2004).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 10(2 Suppl. 1), S115–S120 (2004).
   PubMedGoogle Scholar
• El-Serag HB. Hepatocellular carcinoma. N. Engl. J. Med. 365(12), 1118–1127 (2011).
   PubMed Web of Science ®Google Scholar
• Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J. Gastroenterol. 20(15), 4115–4127 (2014).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35(3), 421–430 (2001).
   PubMed Web of Science ®Google Scholar
• Kawano Y, Sasaki A, Kai S et al. Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann. Surg. Oncol. 15(6), 1670–1676 (2008).
   PubMed Web of Science ®Google Scholar
• Beard RE, Hanto DW, Gautam S, Miksad RA. A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. Surgery 154(3), 545–555 (2013).
   PubMed Web of Science ®Google Scholar
• Santambrogio R, Kluger MD, Costa M et al. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh’s A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB (Oxford) 15(1), 78–84 (2013).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334(11), 693–699 (1996).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Bhoori S, Sposito C et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver transpl. 17(Suppl. 2), S44–S57 (2011).
   PubMed Web of Science ®Google Scholar
• Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J. Hepatol. 55(5), 1137–1147 (2011).
   PubMed Web of Science ®Google Scholar
• Patel SS, Arrington AK, Mckenzie S et al. Milan Criteria and UCSF Criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int. J. Hepatol. 2012, 253517 (2012).
   PubMedGoogle Scholar
• Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25–34 (2009).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Toh HC, Chen PJ, Carr BI et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119(2), 380–387 (2013).
   PubMed Web of Science ®Google Scholar
• Finn RS, Kang YK, Mulcahy M et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 18(7), 2090–2098 (2012).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Abrams TA, Miksad R et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117(22), 5094–5102 (2011).
   PubMed Web of Science ®Google Scholar
• Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat. Oncol. J. 34(3), 160–167 (2016).
   PubMedGoogle Scholar
• Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J. Gastroenterol. 20(12), 3100–3111 (2014).
   PubMed Web of Science ®Google Scholar
• Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin. Radiat. Oncol. 21(4), 294–302 (2011).
   PubMed Web of Science ®Google Scholar
• Kulik LM, Atassi B, Van Holsbeeck L et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J. Surg. Oncol. 94(7), 572–586 (2006).
   PubMed Web of Science ®Google Scholar
• Moreno-Luna LE, Yang JD, Sanchez W et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 36(3), 714–723 (2013).
   PubMed Web of Science ®Google Scholar
• Thomas MB, Jaffe D, Choti MM et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol. 28(25), 3994–4005 (2010).
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J. Hepatol. 56(4), 984–986 (2012).
   PubMed Web of Science ®Google Scholar
• Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148(2), 397–401 (1983).
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 259(3), 641–657 (2011).
   PubMed Web of Science ®Google Scholar
• Golfieri R, Cappelli A, Cucchetti A et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 53(5), 1580–1589 (2011).
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J. Hepatol. 62(5), 1187–1195 (2015).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2), 429–442 (2003).
   PubMed Web of Science ®Google Scholar
• Camma C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224(1), 47–54 (2002).
   PubMed Web of Science ®Google Scholar
• Lammer J, Malagari K, Vogl T et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol. 33(1), 41–52 (2010).
   PubMed Web of Science ®Google Scholar
• Xia J, Ren Z, Ye S et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur. J. Radiol. 59(3), 407–412 (2006).
   PubMed Web of Science ®Google Scholar
• Brown DB, Nikolic B, Covey AM et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J. Vasc. Interv. Radiol. 23(3), 287–294 (2012).
   PubMed Web of Science ®Google Scholar
• Berger DH, Carrasco CH, Hohn DC, Curley SA. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J. Surg. Oncol. 60(2), 116–121 (1995).
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol. 30(1), 6–25 (2007).
   PubMed Web of Science ®Google Scholar
• Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr. Probl. Diagn. Radiol. 38(3), 135–143 (2009).
   PubMedGoogle Scholar
• Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am. J. Roentgenol. 174(2), 323–331 (2000).
   PubMed Web of Science ®Google Scholar
• Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J. Hepatol. 7(8), 1054–1063 (2015).
   PubMed Web of Science ®Google Scholar
• Crocetti L, De Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc. Intervent. Radiol. 33(1), 11–17 (2010).
   PubMed Web of Science ®Google Scholar
• Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47(1), 82–89 (2008).
   PubMed Web of Science ®Google Scholar
• Brunello F, Veltri A, Carucci P et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand. J. Gastroenterol. 43(6), 727–735 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhao Y, Li B et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 10, 78 (2010).
   PubMed Web of Science ®Google Scholar
• Imai K, Beppu T, Chikamoto A et al. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol. Res. 43(8), 853–864 (2013).
   PubMed Web of Science ®Google Scholar
• Choi D, Lim HK, Rhim H et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur. Radiol. 17(3), 684–692 (2007).
   PubMed Web of Science ®Google Scholar
• Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 127(6), 1714–1723 (2004).
   PubMed Web of Science ®Google Scholar
• Takahashi S, Kudo M, Chung H et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 72(Suppl. 1), 98–103 (2007).
   PubMedGoogle Scholar
• De Baere T, Risse O, Kuoch V et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am. J. Roentgenol. 181(3), 695–700 (2003).
   PubMed Web of Science ®Google Scholar
• Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the ’test-of-time approach’. Cancer 97(12), 3027–3035 (2003).
   PubMed Web of Science ®Google Scholar
• Brace CL. Microwave tissue ablation: biophysics, technology, and applications. Crit. Rev. Biomed. Eng. 38(1), 65–78 (2010).
   PubMedGoogle Scholar
• Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics 25(Suppl. 1), S69–S83 (2005).
   PubMed Web of Science ®Google Scholar
• Ward RC, Healey TT, Dupuy DE. Microwave ablation devices for interventional oncology. Expert Rev. Med. Devices 10(2), 225–238 (2013).
   PubMed Web of Science ®Google Scholar
• Shibata T, Iimuro Y, Yamamoto Y et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 223(2), 331–337 (2002).
   PubMed Web of Science ®Google Scholar
• Lloyd DM, Lau KN, Welsh F et al. International multicentre prospective study on microwave ablation of liver tumours: preliminary results. HPB (Oxford). 13(8), 579–585 (2011).
   PubMed Web of Science ®Google Scholar
• Wang T, Lu XJ, Chi JC et al. Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients. Sci. Rep. 6, 32728 (2016).
   PubMed Web of Science ®Google Scholar
• Liang P, Yu J, Lu MD et al. Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy. World J. Gastroenterol. 19(33), 5430–5438 (2013).
   PubMed Web of Science ®Google Scholar
• Buscarini L, Buscarini E, Di Stasi M, Quaretti P, Zangrandi A. Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall Med. 20(2), 47–53 (1999).
   PubMed Web of Science ®Google Scholar
• Bloomston M, Binitie O, Fraiji E et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am. Surg. 68(9), 827–831 (2002).
   PubMed Web of Science ®Google Scholar
• Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 252(3), 905–913 (2009).
   PubMed Web of Science ®Google Scholar
• Gasparini D, Sponza M, Marzio A, Zanardi R, Bazzocchi M, Cemal Y. Combined treatment, TACE and RF ablation, in HCC: preliminary results. La Radiologia medica 104(5–6), 412–420 (2002).
   PubMedGoogle Scholar
• Lee MW, Kim YJ, Park SW et al. Percutaneous radiofrequency ablation of small hepatocellular carcinoma invisible on both ultrasonography and unenhanced CT: a preliminary study of combined treatment with transarterial chemoembolisation. Br. J. Radiol. 82(983), 908–915 (2009).
   PubMed Web of Science ®Google Scholar
• Hyun D, Cho SK, Shin SW, Rhim H, Koh KC, Paik SW. Treatment of small hepatocellular carcinoma (</=2 cm) in the caudate lobe with sequential transcatheter arterial chemoembolization and radiofrequency ablation. Cardiovasc. Intervent. Radiol. 39(7), 1015–1022 (2016).
   PubMed Web of Science ®Google Scholar
• Yang W, Chen MH, Wang MQ et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol. Res. 39(3), 231–240 (2009).
   PubMed Web of Science ®Google Scholar
• Wang X, Hu Y, Ren M, Lu X, Lu G, He S. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J. Radiol. 17(1), 93–102 (2016).
   PubMed Web of Science ®Google Scholar
• Cheng BQ, Jia CQ, Liu CT et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 299(14), 1669–1677 (2008).
   PubMed Web of Science ®Google Scholar
• Kim JH, Won HJ, Shin YM et al. Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann. Surg. Oncol. 18(6), 1624–1629 (2011).
   PubMed Web of Science ®Google Scholar
• Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur. Radiol. 16(3), 661–669 (2006).
   PubMed Web of Science ®Google Scholar
• Tang C, Shen J, Feng W et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma: a retrospective study. Medicine 95(20), e3754 (2016).
   PubMed Web of Science ®Google Scholar
• Chen QW, Ying HF, Gao S et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis. Clin. Res. Hepatol. Gastroenterol. 40(3), 309–314 (2016).
   PubMed Web of Science ®Google Scholar
• Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig. Dis. Sci. 57(11), 3026–3031 (2012).
   PubMed Web of Science ®Google Scholar
• Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur. J. Gastroenterol. Hepatol. 25(2), 187–194 (2013).
   PubMed Web of Science ®Google Scholar
• Gu L, Liu H, Fan L et al. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. J. Cancer Res. Clin. Oncol. 140(2), 199–210 (2014).
   PubMed Web of Science ®Google Scholar
• Seki T, Tamai T, Nakagawa T et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer 89(6), 1245–1251 (2000).
   PubMed Web of Science ®Google Scholar
• Yang WZ, Jiang N, Huang N, Huang JY, Zheng QB, Shen Q. Combined therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation for small hepatocellular carcinoma. World J. Gastroenterol. 15(6), 748–752 (2009).
   PubMed Web of Science ®Google Scholar
• Yi Y, Zhang Y, Wei Q et al. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chin. J. Cancer Res. 26(1), 112–118 (2014).
   PubMed Web of Science ®Google Scholar
• Xu LF, Sun HL, Chen YT et al. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J. Gastroenterol. Hepatol. 28(3), 456–463 (2013).
   PubMed Web of Science ®Google Scholar
• Liu C, Liang P, Liu F et al. MWA combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma. Int. J. Hyperthermia 27(7), 654–662 (2011).
   PubMed Web of Science ®Google Scholar
• Li W, Man W, Guo H, Yang P. Clinical study of transcatheter arterial chemoembolization combined with microwave ablation in the treatment of advanced hepatocellular carcinoma. J. Cancer Res. Ther. 12(Suppl.), C217–C220 (2016).
   PubMed Web of Science ®Google Scholar